-

Eurofins: Weekly Report on Share Repurchases From 01st December to 05th December 2025

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News:

Eurofins (Paris:ERF):

Name of the
Issuer

Identify code of the
Issuer

Transaction
day

Identify code of
the financial
instrument

Total daily
volume (in
number of
shares)

Daily
weighted
average
purchase
price of
the shares

Market
(MIC
Code)

EUROFINS SCIENTIFIC

529900JEHFM47DYY3S57

12/01/2025

FR0014000MR3

20 000

58.9527

XPAR

EUROFINS SCIENTIFIC

529900JEHFM47DYY3S57

12/02/2025

FR0014000MR3

20 000

59.3808

XPAR

EUROFINS SCIENTIFIC

529900JEHFM47DYY3S57

12/03/2025

FR0014000MR3

20 000

58.8687

XPAR

EUROFINS SCIENTIFIC

529900JEHFM47DYY3S57

12/04/2025

FR0014000MR3

20 000

58.8292

XPAR

EUROFINS SCIENTIFIC

529900JEHFM47DYY3S57

12/05/2025

FR0014000MR3

20 000

58.9334

XPAR

 

 

 

TOTAL

100 000

58.9930

 

Transaction details

In accordance with Article 5(1)(b) of Regulation (EU) N° 596/2014 (the Market Abuse Regulation) a full breakdown of the individual trades are disclosed on Eurofins Scientific SE website: https://www.eurofins.com/investors/share-buy-back-programmes

Contacts

Eurofins

Eurofins

BOURSE:ERF
Release Versions
English

Contacts

Eurofins

More News From Eurofins

Eurofins Scientific SE: Weekly Report on Share Repurchases from 02nd February to 06th February 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 02/02/2026 FR0014000MR3 10 000 68.3375 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 03/02/2026 FR0014000MR3 10 000 67.9091 XPAR EUROFINS SCIENTIFIC 529900JEHFM...

Eurofins Viracor BioPharma Expands Bioanalytical Capabilities

LUXEMBOURG--(BUSINESS WIRE)--Eurofins Viracor BioPharma Services, a long‑standing and trusted partner for clinical trial testing solutions with deep expertise in specialty biomarkers and molecular assays, announces a significant expansion of its service portfolio with the addition of enhanced bioanalytical testing capabilities. These new services are fully aligned with Good Laboratory Practices (GLP) and Good Clinical Practices (GCP), enabling the company to enhance support of biopharmaceutical...

Eurofins CDMO Alphora Joins International Consortium Project to Advance Next Generation ADC Expression Platform

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Eurofins CDMO Alphora is pleased to announce that its Canadian-based division is receiving advisory services and funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support a research and development collaboration project focused on advancing a transformative approach for next-generation ADC (antibody-drug conjugate) production to meet the growing demand for targeted therapeutics. As part of this initia...
Back to Newsroom